The procalcitonin (PCT) assay market size is projected to be worth US$ 280.6 million in 2023. The market is likely to surpass US$ 512.9 million by 2033 at a CAGR of 6.2% during the forecast period. Growing lung cancer incidences is aiding the market growth. The PCT assay market has seen significant growth in recent years due to the increasing awareness about the importance of early and accurate diagnosis of bacterial infections The Procalcitonin (PCT) assay refers to the market for diagnostic tests that measure the levels of procalcitonin in the bloodstream. Procalcitonin is a precursor protein to the hormone calcitonin and is produced in response to bacterial infections.
Other Drivers Propelling the Demand for Procalcitonin (PCT) Assay Market include:
Challenges for Companies /Manufacturers in the Procalcitonin (PCT) Assay Market:
Opportunities in the Procalcitonin (PCT) Assay Market Industry:
Latest Trends in the Procalcitonin (PCT) Assay Market:
| Attributes | Details |
|---|---|
| Procalcitonin (PCT) Assay Market Size (2023) | US$ 280.6 million |
| Procalcitonin (PCT) Assay Market Projected Size (2033) | US$ 512.9 million |
| Value CAGR (2023 to 2033) | 6.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2012 to 2022, the global procalcitonin (PCT) assay market experienced a CAGR of 3.0%, reaching a market size of US$ 280.6 million in 2023.
The global procalcitonin (PCT) assay market witnessed steady growth in the past and is expected to continue to develop at a significant pace due to their increasing demand in non-hospital settings, such as primary care clinics and outpatient facilities. The increasing availability of PCT testing options, including point-of-care devices, facilitates broader access to PCT testing and supports early diagnosis and appropriate management of bacterial infections in various healthcare settings.
With the rising concern of antibiotic resistance, there is an increased emphasis on antibiotic stewardship programs. PCT assays play a vital role in these programs by assisting clinicians in determining the need for antibiotic therapy, optimizing treatment duration, and monitoring response to treatment. This is also leading to enhanced integration of PCT testing into antibiotic stewardship protocols.
Future Forecast for Procalcitonin (PCT) Assay Market Industry:
Looking ahead, the global procalcitonin (PCT) assay market is expected to rise at a CAGR of 6.2% from 2023 to 2033. During the forecast period, the market size is expected to reach US$ 512.9 million by 2033.
PCT is increasingly being used as part of biomarker panels or algorithms to improve the accuracy of infection diagnosis and prognosis. Combining PCT with other biomarkers, such as C-reactive protein (CRP) or proadrenomedullin (MR-proADM), can provide a more comprehensive assessment of the severity and course of an infection, this could likely increase the sales of PCT assays in the coming times.
Collaboration between diagnostic companies, assay manufacturers, and healthcare providers is becoming more prevalent. Partnerships and collaborations among manufactures will combine expertise, resources, and technologies to develop innovative PCT assays, improve accessibility, and expand market reach. These partnerships can lead to the development of integrated diagnostic solutions and improved patient care.
| Country | The United States |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 202.0 million |
| CAGR % 2023 to End of Forecast (2033) | 7.3% |
The procalcitonin (PCT) assay market in the United States is expected to reach a market size of US$ 202.0 million by 2033, expanding at a CAGR of 7.3%. The United States has been experiencing a rising incidence of bacterial infections, including community-acquired pneumonia, sepsis, and urinary tract infections. This has heightened the need for accurate and timely diagnosis to guide appropriate treatment decisions. PCT assays offer valuable insights for differentiating bacterial from viral infections, aiding in the diagnosis and management of these conditions.
| Country | The United Kingdom |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 26.4 million |
| CAGR % 2023 to End of Forecast (2033) | 8.3% |
The procalcitonin (PCT) assay market in the United Kingdom is expected to reach a market value of US$ 26.4 million, expanding at a CAGR of 8.3% during the forecast period. The availability of favorable reimbursement policies for PCT testing has played a role in the market growth of PCT assays in the UK. Reimbursement coverage by public and private payers incentivizes healthcare providers to adopt and utilize PCT assays, ensuring proper compensation for the testing services provided.
| Country | China |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 62.7 million |
| CAGR % 2023 to End of Forecast (2033) | 9.1% |
The procalcitonin (PCT) assay market in China is anticipated to reach a market size of US$ 62.7 million by the end of 2033, growing at a CAGR of 9.1% throughout the forecast period. There has been a significant increase in awareness among healthcare professionals in China about the clinical utility and benefits of PCT testing. Educational initiatives, conferences, and scientific publications have contributed to the dissemination of knowledge regarding PCT assays and their role in infection management. This improved awareness has led to increased demand for PCT assays in the country.
| Country | Japan |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 20.8 million |
| CAGR % 2023 to End of Forecast (2033) | 6.7% |
The procalcitonin (PCT) assay market in Japan is estimated to reach a market size of US$ 20.8 million by 2033, expected to thrive at a CAGR of 6.7%. Technological advancements have improved the accessibility and efficiency of PCT assays. Automated platforms, rapid testing options, and point-of-care devices have made PCT testing more convenient and streamlined in various healthcare settings. These advancements have facilitated the integration of PCT assays into routine clinical practice, leading to their surge in the Japan.
| Country | South Korea |
|---|---|
| Market Size (US$ Million) by End of Forecast Period (2033) | US$ 13.9 million |
| CAGR % 2023 to End of Forecast (2033) | 6.0% |
The procalcitonin (PCT) assay market in South Korea is expected to reach a market size of US$ 13.9 million, expanding at a CAGR of 6.0% during the forecast period. South Korea has a robust healthcare infrastructure, including hospitals, clinics, and diagnostic laboratories. This infrastructure supports the implementation and utilization of PCT assays in routine practice. The presence of well-equipped healthcare facilities and the availability of trained personnel contribute to the increased demand for PCT assays in the country.
Principal Consultant
Serum sample dominated the procalcitonin (PCT) assay market with a market share of 34.2% in 2022. Collecting serum samples is a routine and minimally invasive procedure. Blood samples can be easily obtained through venipuncture and processed to separate serum and plasma from other blood components. This simplicity and familiarity make serum a convenient sample type for PCT assay testing.
Based on products, test kits have dominated the category withholding the significant share of the market at around 68.7% at the end of 2022. Test kits for PCT assays are readily available in the market from multiple manufacturers. This wide availability ensures that laboratories and healthcare facilities have access to a variety of options, allowing them to select the test kit that best fits their specific requirements in terms of performance, cost, and workflow compatibility.
By purpose, clinical use segment is expected to continue leading the market over a CAGR of 6.0% throughout the projected timeframe. PCT assays have proven clinical utility in the diagnosis of bacterial infections, especially severe infections such as sepsis. PCT levels in the bloodstream rise significantly in response to bacterial infections, making it a valuable biomarker for differentiating bacterial from viral infections. This diagnostic value has led to the widespread adoption of PCT assays in clinical practice for guiding antibiotic therapy and supporting clinical decision-making.
The hospitals have led the procalcitonin (PCT) assay market as the leading end user with the market share of 36.7% in 2022. Hospitals are primary providers of acute care, dealing with a wide range of patients, including those with severe infections, sepsis, and other critical conditions. PCT assays have significant clinical utility in these settings, aiding in the diagnosis, monitoring, and management of bacterial infections. Hospitals rely on PCT assays to support clinical decision-making, guide antibiotic therapy, and assess patient prognosis in these acute care scenarios.
By employing these strategies, key players in the PCT assay market can enhance their competitiveness, differentiate their offerings, and maintain a strong market presence. Continuous innovation, strategic partnerships, effective marketing, and customer-centric approaches are crucial for sustained success in this competitive industry.
Key Strategies Used by the Participants
Key players continuously invest in research and development to introduce innovative PCT assay products. They strive to develop assays with improved sensitivity, specificity, accuracy, and ease of use.
Key players often form strategic partnerships and collaborations with other companies, research institutions, and healthcare organizations. These partnerships can lead to knowledge sharing, joint product development, and expanded market reach.
Expanding into emerging markets with growing healthcare infrastructure and rising demand for PCT assays allows companies to tap into new opportunities and gain a competitive edge.
Companies in the market may engage in mergers or acquisitions to streamline their product portfolio, obtain new technologies, enter new market niches, and gain access to novel products or intellectual property.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Procalcitonin (PCT) Assay Market:
The global procalcitonin (PCT) assay market is expected to reach a valuation of US$ 280.6 million by 2023.
The procalcitonin (PCT) assay market demand is set to expand by 6.2% during the assessment period.
The test kits segment is projected to hold the dominant share of the market.
The market is predicted to exceed US$ 512.9 million by 2033.
The North America offers key opportunities for new entrants in the procalcitonin (PCT) assay market.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. FMI Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Trends
3.1. Key Trends Impacting the Market
3.2. Innovation/Development Trends
4. Value Added Insights
4.1. Product Adoption / Usage Analysis, by Region
4.2. New Product Launches
4.3. Regulatory Landscape, By Country
4.4. PESTEL Analysis
4.5. Porter’s Five Force Analysis
4.6. Value Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Immunoassay Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increasing Incidence of Sepsis and Infectious Diseases
5.2.2. Growing Emphasis on Antibiotic Stewardship
5.2.3. Increasing Awareness about PCT as a Biomarker
5.2.4. Continuous Advancements in Assay Technologies, Including Immunoassays, Molecular Diagnostics, and Point-Of-Care Testing
5.2.5. Expansion into Non-Hospital Settings
5.2.6. Investments in Research and Development
5.2.7. Emerging Markets and Increased Healthcare Spending
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunities
6. Global Market Demand Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033
6.1. Historical Market Volume (Units) Analysis, 2012 to 2022
6.2. Current and Future Market Volume (Units) Projections, 2023 to 2033
6.2.1. Y-o-Y Growth Trend Analysis
7. Global Market Demand Pricing Analysis 2012 to 2022 and Forecast, 2023 to 2033
7.1. Regional Pricing Analysis
7.2. Pricing Break-up
7.2.1. Manufacturer Level Pricing
7.2.2. Distributor Level Pricing
7.3. Global Average Pricing Analysis
7.4. Pricing Assumptions
8. Global Market Demand (in Value or Size in US$ Mn) Analysis 2012 to 2022 and Forecast, 2023 to 2033
8.1. Revenue Opportunity Scenario- Likely/Conservative/Optimistic
8.2. Historical Market Value (US$ Million) Analysis, 2012 to 2022
8.3. Current and Future Market Value (US$ Million) Projections, 2023 to 2033
8.3.1. Y-o-Y Growth Trend Analysis
8.3.2. Absolute $ Opportunity Analysis
9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Sample Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis By Sample Type, 2012 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Sample Type, 2023 to 2033
9.3.1. Serum
9.3.2. Plasma
9.3.3. Cell Culture Medium
9.3.4. Other Biological Fluids
9.4. Market Attractiveness Analysis By Sample Type
10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) and Volume (Unit) By Product, 2012 to 2022
10.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2023 to 2033
10.3.1. Test Kits
10.3.1.1. Procalcitonin ELISA test kits
10.3.1.2. Procalcitonin CLIA kits
10.3.1.3. PCT Immunochromatography KITS
10.3.1.4. PCT Rapid Test Kit
10.3.2. Analyzer & Instrument
10.3.3. Consumable
10.4. Market Attractiveness Analysis By Product
11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Purpose
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis By Purpose, 2012 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Purpose, 2023 to 2033
11.3.1. Clinical Use
11.3.2. Research Use Only
11.4. Market Attractiveness Analysis By Purpose
12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User
12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033
12.3.1. Hospital
12.3.2. Specialty Clinics
12.3.3. Academic and Research Institute
12.3.4. Diagnostics Laboratories
12.4. Market Attractiveness Analysis By End User
13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region
13.1. Introduction
13.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Region, 2012 to 2022
13.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Region, 2023 to 2033
13.3.1. North America
13.3.2. Latin America
13.3.3. Europe
13.3.4. South Asia
13.3.5. East Asia
13.3.6. Oceania
13.3.7. Middle East & Africa
13.4. Market Attractiveness Analysis By Region
14. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022
14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. USA
14.3.1.2. Canada
14.3.2. By Sample Type
14.3.3. By Product
14.3.4. By Purpose
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Sample Type
14.4.3. By Product
14.4.4. By Purpose
14.4.5. By End User
14.5. Market Trends
14.6. Market Drivers & Restraints – Impact Analysis
14.7. Country Level Analysis & Forecast
14.7.1. USA Market
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Sample Type
14.7.1.2.2. By Product
14.7.1.2.3. By Purpose
14.7.1.2.4. By End User
14.7.2. Canada Market
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Sample Type
14.7.2.2.2. By Product
14.7.2.2.3. By Purpose
14.7.2.2.4. By End User
15. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022
15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Brazil
15.3.1.2. Mexico
15.3.1.3. Argentina
15.3.1.4. Rest of LATAM
15.3.2. By Sample Type
15.3.3. By Product
15.3.4. By Purpose
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Sample Type
15.4.3. By Product
15.4.4. By Purpose
15.4.5. By End User
15.5. Market Trends
15.6. Market Drivers & Restraints – Impact Analysis
15.7. Country Level Analysis & Forecast
15.7.1. Brazil Market
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Sample Type
15.7.1.2.2. By Product
15.7.1.2.3. By Purpose
15.7.1.2.4. By End User
15.7.2. Mexico Market
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Sample Type
15.7.2.2.2. By Product
15.7.2.2.3. By Purpose
15.7.2.2.4. By End User
15.7.3. Argentina Market
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Sample Type
15.7.3.2.2. By Product
15.7.3.2.3. By Purpose
15.7.3.2.4. By End User
16. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022
16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. UK
16.3.1.2. Germany
16.3.1.3. France
16.3.1.4. Italy
16.3.1.5. Spain
16.3.1.6. BENELUX
16.3.1.7. Russia
16.3.1.8. Rest of Europe
16.3.2. By Sample Type
16.3.3. By Product
16.3.4. By Purpose
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Sample Type
16.4.3. By Product
16.4.4. By Purpose
16.4.5. By End User
16.5. Market Trends
16.6. Market Drivers & Restraints – Impact Analysis
16.7. Country Level Analysis & Forecast
16.7.1. UK Market
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Sample Type
16.7.1.2.2. By Product
16.7.1.2.3. By Purpose
16.7.1.2.4. By End User
16.7.2. Germany Market
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Sample Type
16.7.2.2.2. By Product
16.7.2.2.3. By Purpose
16.7.2.2.4. By End User
16.7.3. France Market
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Sample Type
16.7.3.2.2. By Product
16.7.3.2.3. By Purpose
16.7.3.2.4. By End User
16.7.4. Italy Market
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Sample Type
16.7.4.2.2. By Product
16.7.4.2.3. By Purpose
16.7.4.2.4. By End User
16.7.5. Spain Market
16.7.5.1. Introduction
16.7.5.2. Market Analysis and Forecast by Market Taxonomy
16.7.5.2.1. By Sample Type
16.7.5.2.2. By Product
16.7.5.2.3. By Purpose
16.7.5.2.4. By End User
16.7.6. BENELUX Market
16.7.6.1. Introduction
16.7.6.2. Market Analysis and Forecast by Market Taxonomy
16.7.6.2.1. By Sample Type
16.7.6.2.2. By Purpose
16.7.6.2.3. By Product
16.7.6.2.4. By End User
16.7.7. Russia Market
16.7.7.1. Introduction
16.7.7.2. Market Analysis and Forecast by Market Taxonomy
16.7.7.2.1. By Sample Type
16.7.7.2.2. By Product
16.7.7.2.3. By Purpose
16.7.7.2.4. By End User
17. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022
17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Sample Type
17.3.3. By Product
17.3.4. By Purpose
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Sample Type
17.4.3. By Product
17.4.4. By Purpose
17.4.5. By End User
17.5. Market Trends
17.6. Market Drivers & Restraints – Impact Analysis
17.7. Country Level Analysis & Forecast
17.7.1. China Market
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Sample Type
17.7.1.2.2. By Product
17.7.1.2.3. By Purpose
17.7.1.2.4. By End User
17.7.2. Japan Market
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Sample Type
17.7.2.2.2. By Product
17.7.2.2.3. By Purpose
17.7.2.2.4. By End User
17.7.3. South Korea Market
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Sample Type
17.7.3.2.2. By Product
17.7.3.2.3. By Purpose
17.7.3.2.4. By End User
18. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022
18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. India
18.3.1.2. Indonesia
18.3.1.3. Thailand
18.3.1.4. Malaysia
18.3.1.5. Rest of South Asia
18.3.2. By Sample Type
18.3.3. By Product
18.3.4. By Purpose
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Sample Type
18.4.3. By Product
18.4.4. By Purpose
18.4.5. By End User
18.5. Market Trends
18.6. Market Drivers & Restraints – Impact Analysis
18.7. Country Level Analysis & Forecast
18.7.1. India Market
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Sample Type
18.7.1.2.2. By Product
18.7.1.2.3. By Purpose
18.7.1.2.4. By End User
18.7.2. Indonesia Market
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Sample Type
18.7.2.2.2. By Product
18.7.2.2.3. By Purpose
18.7.2.2.4. By End User
18.7.3. Thailand Market
18.7.3.1. Introduction
18.7.3.2. Market Analysis and Forecast by Market Taxonomy
18.7.3.2.1. By Sample Type
18.7.3.2.2. By Product
18.7.3.2.3. By Purpose
18.7.3.2.4. By End User
18.7.4. Malaysia Market
18.7.4.1. Introduction
18.7.4.2. Market Analysis and Forecast by Market Taxonomy
18.7.4.2.1. By Sample Type
18.7.4.2.2. By Product
18.7.4.2.3. By Purpose
18.7.4.2.4. By End User
19. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022
19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. Australia
19.3.1.2. New Zealand
19.3.2. By Sample Type
19.3.3. By Product
19.3.4. By Purpose
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Sample Type
19.4.3. By Product
19.4.4. By Purpose
19.4.5. By End User
19.5. Market Trends
19.6. Market Drivers & Restraints – Impact Analysis
19.7. Country Level Analysis & Forecast
19.7.1. Australia Market
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Sample Type
19.7.1.2.2. By Product
19.7.1.2.3. By Purpose
19.7.1.2.4. By End User
19.7.2. New Zealand Market
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Sample Type
19.7.2.2.2. By Product
19.7.2.2.3. By Purpose
19.7.2.2.4. By End User
20. Middle East & Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033
20.1. Introduction
20.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2012 to 2022
20.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033
20.3.1. By Country
20.3.1.1. GCC Countries
20.3.1.2. Türkiye
20.3.1.3. South Africa
20.3.1.4. Northern Africa
20.3.1.5. Rest of Middle East and Africa
20.3.2. By Sample Type
20.3.3. By Product
20.3.4. By Purpose
20.3.5. By End User
20.4. Market Attractiveness Analysis
20.4.1. By Country
20.4.2. By Sample Type
20.4.3. By Product
20.4.4. By Purpose
20.4.5. By End User
20.5. Market Trends
20.6. Market Drivers & Restraints – Impact Analysis
20.7. Country Level Analysis & Forecast
20.7.1. GCC Countries Market
20.7.1.1. Introduction
20.7.1.2. Market Analysis and Forecast by Market Taxonomy
20.7.1.2.1. By Sample Type
20.7.1.2.2. By Product
20.7.1.2.3. By Purpose
20.7.1.2.4. By End User
20.7.2. Türkiye Market
20.7.2.1. Introduction
20.7.2.2. Market Analysis and Forecast by Market Taxonomy
20.7.2.2.1. By Sample Type
20.7.2.2.2. By Product
20.7.2.2.3. By Purpose
20.7.2.2.4. By End User
20.7.3. South Africa Market
20.7.3.1. Introduction
20.7.3.2. Market Analysis and Forecast by Market Taxonomy
20.7.3.2.1. By Sample Type
20.7.3.2.2. By Product
20.7.3.2.3. By Purpose
20.7.3.2.4. By End User
20.7.4. Northern Africa Market
20.7.4.1. Introduction
20.7.4.2. Market Analysis and Forecast by Market Taxonomy
20.7.4.2.1. By Sample Type
20.7.4.2.2. By Product
20.7.4.2.3. By Purpose
20.7.4.2.4. By End User
21. Market Structure Analysis
21.1. Market Analysis by Tier of Companies (Maternity Care Types)
21.2. Market Share Analysis of Top Players
21.3. Market Concentration
22. Competition Analysis
22.1. Competition Dashboard
22.2. Branding and Promotional Strategies, By key Players
22.3. Key Development Analysis
22.4. Competition Deep Dive
22.4.1. Thermo Fisher Scientific Inc.
22.4.1.1. Overview
22.4.1.2. Type Portfolio
22.4.1.3. Key Financials
22.4.1.4. SWOT Analysis
22.4.1.5. Key Developments
22.4.1.6. Sales Footprint
22.4.1.7. Strategy Overview
22.4.1.7.1. Marketing Strategy
22.4.1.7.2. Type Strategy
22.4.1.7.3. Channel Strategy
22.4.2. J. Mitra & Co. Pvt. Ltd.
22.4.2.1. Overview
22.4.2.2. Type Portfolio
22.4.2.3. Key Financials
22.4.2.4. SWOT Analysis
22.4.2.5. Key Developments
22.4.2.6. Sales Footprint
22.4.2.7. Strategy Overview
22.4.2.7.1. Marketing Strategy
22.4.2.7.2. Type Strategy
22.4.2.7.3. Channel Strategy
22.4.3. Thermo Fisher Scientific Inc.
22.4.3.1. Overview
22.4.3.2. Type Portfolio
22.4.3.3. Key Financials
22.4.3.4. SWOT Analysis
22.4.3.5. Key Developments
22.4.3.6. Sales Footprint
22.4.3.7. Strategy Overview
22.4.3.7.1. Marketing Strategy
22.4.3.7.2. Type Strategy
22.4.3.7.3. Channel Strategy
22.4.4. Elabscience Biotechnology Inc.
22.4.4.1. Overview
22.4.4.2. Type Portfolio
22.4.4.3. Key Financials
22.4.4.4. SWOT Analysis
22.4.4.5. Key Developments
22.4.4.6. Sales Footprint
22.4.4.7. Strategy Overview
22.4.4.7.1. Marketing Strategy
22.4.4.7.2. Type Strategy
22.4.4.7.3. Channel Strategy
22.4.5. CUSABIO TECHNOLOGY LLC
22.4.5.1. Overview
22.4.5.2. Type Portfolio
22.4.5.3. Key Financials
22.4.5.4. SWOT Analysis
22.4.5.5. Key Developments
22.4.5.6. Sales Footprint
22.4.5.7. Strategy Overview
22.4.5.7.1. Marketing Strategy
22.4.5.7.2. Type Strategy
22.4.5.7.3. Channel Strategy
22.4.6. Wuhan Fine Biotech Co., Ltd.
22.4.6.1. Overview
22.4.6.2. Type Portfolio
22.4.6.3. Key Financials
22.4.6.4. SWOT Analysis
22.4.6.5. Key Developments
22.4.6.6. Sales Footprint
22.4.6.7. Strategy Overview
22.4.6.7.1. Marketing Strategy
22.4.6.7.2. Type Strategy
22.4.6.7.3. Channel Strategy
22.4.7. Company ABclonal, Inc.
22.4.7.1. Overview
22.4.7.2. Type Portfolio
22.4.7.3. Key Financials
22.4.7.4. SWOT Analysis
22.4.7.5. Key Developments
22.4.7.6. Sales Footprint
22.4.7.7. Strategy Overview
22.4.7.7.1. Marketing Strategy
22.4.7.7.2. Type Strategy
22.4.7.7.3. Channel Strategy
22.4.8. Nanjing Vazyme Biotech Co.,Ltd.
22.4.8.1. Overview
22.4.8.2. Type Portfolio
22.4.8.3. Key Financials
22.4.8.4. SWOT Analysis
22.4.8.5. Key Developments
22.4.8.6. Sales Footprint
22.4.8.7. Strategy Overview
22.4.8.7.1. Marketing Strategy
22.4.8.7.2. Type Strategy
22.4.8.7.3. Channel Strategy
22.4.9. RayBiotech Life, Inc.
22.4.9.1. Overview
22.4.9.2. Type Portfolio
22.4.9.3. Key Financials
22.4.9.4. SWOT Analysis
22.4.9.5. Key Developments
22.4.9.6. Sales Footprint
22.4.9.7. Strategy Overview
22.4.9.7.1. Marketing Strategy
22.4.9.7.2. Type Strategy
22.4.9.7.3. Channel Strategy
22.4.10. Hipro Biotechnology Co.,Ltd.
22.4.10.1. Overview
22.4.10.2. Type Portfolio
22.4.10.3. Key Financials
22.4.10.4. SWOT Analysis
22.4.10.5. Key Developments
22.4.10.6. Sales Footprint
22.4.10.7. Strategy Overview
22.4.10.7.1. Marketing Strategy
22.4.10.7.2. Type Strategy
22.4.10.7.3. Channel Strategy
22.4.11. Vitrosens Biotechnology
22.4.11.1. Overview
22.4.11.2. Type Portfolio
22.4.11.3. Key Financials
22.4.11.4. SWOT Analysis
22.4.11.5. Key Developments
22.4.11.6. Sales Footprint
22.4.11.7. Strategy Overview
22.4.11.7.1. Marketing Strategy
22.4.11.7.2. Type Strategy
22.4.11.7.3. Channel Strategy
22.4.12. bioMérieux SA
22.4.12.1. Overview
22.4.12.2. Type Portfolio
22.4.12.3. Key Financials
22.4.12.4. SWOT Analysis
22.4.12.5. Key Developments
22.4.12.6. Sales Footprint
22.4.12.7. Strategy Overview
22.4.12.7.1. Marketing Strategy
22.4.12.7.2. Type Strategy
22.4.12.7.3. Channel Strategy
22.4.13. ELK Biotechnology CO.,Ltd.
22.4.13.1. Overview
22.4.13.2. Type Portfolio
22.4.13.3. Key Financials
22.4.13.4. SWOT Analysis
22.4.13.5. Key Developments
22.4.13.6. Sales Footprint
22.4.13.7. Strategy Overview
22.4.13.7.1. Marketing Strategy
22.4.13.7.2. Type Strategy
22.4.13.7.3. Channel Strategy
22.4.14. Immuno-Biological Laboratories, Inc.
22.4.14.1. Overview
22.4.14.2. Type Portfolio
22.4.14.3. Key Financials
22.4.14.4. SWOT Analysis
22.4.14.5. Key Developments
22.4.14.6. Sales Footprint
22.4.14.7. Strategy Overview
22.4.14.7.1. Marketing Strategy
22.4.14.7.2. Type Strategy
22.4.14.7.3. Channel Strategy
22.4.15. BISAF
22.4.15.1. Overview
22.4.15.2. Type Portfolio
22.4.15.3. Key Financials
22.4.15.4. SWOT Analysis
22.4.15.5. Key Developments
22.4.15.6. Sales Footprint
22.4.15.7. Strategy Overview
22.4.15.7.1. Marketing Strategy
22.4.15.7.2. Type Strategy
22.4.15.7.3. Channel Strategy
22.4.16. Roche Diagnostics
22.4.16.1. Overview
22.4.16.2. Type Portfolio
22.4.16.3. Key Financials
22.4.16.4. SWOT Analysis
22.4.16.5. Key Developments
22.4.16.6. Sales Footprint
22.4.16.7. Strategy Overview
22.4.16.7.1. Marketing Strategy
22.4.16.7.2. Type Strategy
22.4.16.7.3. Channel Strategy
23. Assumptions and Acronyms Used
24. Research Methodology
Explore Healthcare Insights
View Reports
Procalcitonin (PCT) Assay Market
